Review RPM International's (RPM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Explore how Dover's (DOV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Examine Equifax's (EFX) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Explore how Tesla's (TSLA) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Explore Lamb Weston's (LW) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

VALE braces for declines in Q2 sales and earnings, with weak iron ore prices and lower volumes offsetting volume gains in copper and nickel.

UIS' Q2 results may reflect growth in AI and digital workplace wins, tempered by L&S timing and margin pressures.

NEE and SO are both betting big on renewables; see how they compare on earnings growth, dividends, and price performance.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The Ensign Group, Inc.'s regional network strategy drives strong growth, operational efficiency, and quality, but faces persistent labor shortages and regulatory headwinds. Recent earnings and occupancy trends are impressive, supported by a solid balance sheet and flexible real estate approach, but growth now requires heavy upfront investment. Valuation is stretched: ENSG shares trade at a 66% premium to fair value, with high multiples only justified by flawless execution and uninterrupted growth.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ZEEKR Intelligent Technology Holding Limited (“Zeekr” or the “Company”) (NYSE: ZK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Centrus Energy boasts HALEU leadership and soaring sales; NexGen Energy holds a high-grade asset poised to reshape uranium production.

Cameco is set to post sharply higher Q2 revenues and EPS, but an earnings beat may remain out of reach.

SPYG hits a 52-week high as growth stocks surge on strong earnings, easing inflation and rate cut hopes.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Many defined contribution (DC) plans remain unconvinced that members are on track for sufficient income in retirement and expect the time frame to reverse this to take decades, according to new research by leading global advisory, broking and solutions company WTW's (NASDAQ: WTW) Thinking Ahead Institute.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The $16 million center is managed by Community Health Development, Inc., and offers healthcare services, community support, and other resources UVALDE, Texas , July 28, 2025 /PRNewswire/ -- Superior HealthPlan and the Centene Foundation, the philanthropic arm of Centene (NYSE: CNC), today joined Community Health Development, Inc. (CHDI) to open a new $16 million multi-purpose community health center in Uvalde. The 16,000-square-foot space provides healthcare services, community support and outreach, education and workforce development, and a meeting space for the Uvalde community and the surrounding region.